Business UpdateAug 11, 2026, 07:02 AM
Aura Biosciences Refocuses on Ocular Oncology; Phase 3 Trial Fully Enrolled
AI Summary
Aura Biosciences announced a strategic refocus on ocular oncology, deprioritizing its NMIBC program despite encouraging interim data, to concentrate resources on bel-sar development. The company fully enrolled its Phase 3 CoMpass trial for early choroidal melanoma with 108 patients, exceeding targets, and expects topline data in 2H 2027. This strategic shift includes an organizational restructuring, a 20% workforce reduction, and new executive appointments, extending the cash runway into 1H 2029. For Q2 2026, the net loss was $45.6 million, up from $27.0 million in Q2 2025, with cash and equivalents totaling $323.8 million.
Key Highlights
- Strategic refocus on ocular oncology, deprioritizing NMIBC program.
- Phase 3 CoMpass trial fully enrolled with 108 patients, exceeding target.
- Topline data for Phase 3 CoMpass trial expected in 2H 2027.
- Organizational restructuring includes 20% workforce reduction.
- Cash runway extended into 1H 2029 due to restructuring and capital allocation.
- Appointed new COO, Chief Regulatory & Quality Officer, and Chief People Officer.
- Q2 2026 net loss was $45.6 million, up from $27.0 million in Q2 2025.
- Cash and marketable securities totaled $323.8 million as of June 30, 2026.
Price Impact
More from AURA